arterioscope is an AI-powered ECG analytics and digital biomarker platform for clinical trials and next-generation devices. The company's clinically validated AI engine interprets ECG signals with high precision, helping small and mid-sized biotech companies detect drug effects earlier and reduce false negatives in small cohorts. The platform is designed for research use only, supporting Phase I/II trials with deeper cardiac insights from standard ECG data.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Small and mid-sized biotech companies conducting early-phase clinical trials often struggle to extract meaningful cardiac signals from standard ECG data, particularly in small cohorts where drug effects can be subtle and patient heterogeneity introduces noise. This makes it difficult to detect treatment effects early, identify responder subgroups, and make confident go/no-go decisions, increasing development risk.
Solution
arterioscope provides an AI-powered ECG analytics and digital biomarker platform that transforms routine ECG data into deeper cardiac intelligence. The core technology is a clinically validated AI engine that interprets ECG signals with high precision, validated across multi-site clinical datasets. The platform is designed for research use only and helps biotech companies reveal early treatment signals in small Phase I/II trials, identify responder subgroups, and reduce noise from heterogeneous patient populations. By delivering deeper insights from standard ECG data, arterioscope enables earlier go/no-go decisions and lowers development risk for its customers.
Target Audience
Primary customers are small and mid-sized biotech companies conducting Phase I/II clinical trials, as well as developers of next-generation ECG-enabled medical devices seeking advanced cardiac analytics.
Features
- Clinically validated AI engine for high-precision ECG signal interpretation, proven across multi-site clinical datasets
- Digital biomarker platform that extracts cardiac intelligence from routine ECG data for research and clinical trials
- RUO (Research Use Only) analytics platform tailored for small and mid-sized biotech companies
- Capabilities for detecting drug effects early, identifying responder subgroups, and reducing noise from heterogeneous patient populations
- Designed to support Phase I/II trial workflows with deeper cardiac insights from standard ECG recordings